Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONX-0801 in solid tumours
NCT02360345Phase 1Completed
- Sponsor
- Royal Marsden NHS Foundation Trust
- Start
- Sep 2013
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of CT900 in solid tumor, ovarian cancer and endometrial cancer (EC) (2 arms), sponsored by Royal Marsden NHS Foundation Trust. Primary endpoints: Maximum Tolerated Dose and Safety and Toxicity Profile. Started Sep 2013; status: completed.
02
Drugs
CT900
03
Conditions
solid tumorovarian cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NCT02360345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02360345.